of all six pro-survival Bcl-2 family members to ABT-737 resistance has never been compared side-by-side in a cellular context. Combination of ABT-737 with various anticancer drugs often leads to increased cell death, 9 but these compounds often induce multiple BH3-only proteins. 8 How individual BH3-only proteins contribute to synergy with ABT-737 is therefore unclear.
We present here the selectivity of ABT-737 for all human full-length pro-survival Bcl-2 family members in human p53 wild-type and -mutant T-leukemic cells. Bcl-B was identified as mediator of ABT-737 resistance, like Mcl-1 and Bfl-1 were previously, [14] [15] [16] in accordance with the low affinity of ABT-737 for these pro-survival proteins in vitro. Contrary to in vitro affinity studies, however, we find that ABT-737 targets Bcl-2 with preference over Bcl-xL and Bcl-w. BH3-only protein and Bax displacement revealed that ABT-737 differs in its ability to disrupt complexes between these proteins and Bcl-2, Bcl-xL or Bcl-w. This explains the differential targeting of these proteins in the cellular context. Using cell lines with inducible expression of Noxa, Bim, Puma or truncated Bid, we found that only Noxa could synergize with ABT-737 in cells expressing the untargeted proteins Bcl-B, Bfl-1 or Mcl-1. Accordingly, Noxa-inducing anticancer drug bortezomib synergized with ABT-737 in case of Bcl-B, Bfl-1 or Mcl-1 overexpression. These data provide additional guidelines for design and selection of novel BH3-mimetic drugs.
Results
In a cellular context, ABT-737 targets Bcl-2 with greater efficiency than all other pro-survival proteins. For this study, we used the two well-characterized human T-acute lymphoblastic leukemia (T-ALL) cell lines MOLT-4 and J16 that have a wild-type and mutant p53 status, respectively. We stably expressed each of the six pro-survival Bcl-2 proteins in these cell lines by retroviral transduction. Overexpression of the Bcl-2 proteins was confirmed by western blotting (Supplementary Figure 1) . To determine their sensitivity to ABT-737, the cell lines were cultured for 48 h with a dose range of the drug or its negative enantiomer, and cell death was read out by propidium iodide (PI) uptake. Cell death was classified as apoptosis by nuclear fragmentation and complete inhibition by the pan-caspase inhibitor z-VADfmk (Supplementary Figure 2) . Cell death induced by the enantiomer was differentially inhibited by the various Bcl-2 family members, and therefore this compound was disqualified as a control (Supplementary Figure 3) .
MOLT-4 and J16 empty-vector control cell lines died in a dose-dependent manner in response to ABT-737 treatment ( Figure 1a) , with EC 50 values of about 0.1 mM and 8 mM, respectively (Figure 1b ). For the cell lines overexpressing the different Bcl-2 family members, we have depicted the fitted response curve of the empty-vector control cells in each plot, as a reference for ABT-737 sensitivity (Figure 1a ). Both MOLT-4 and J16 cells that overexpressed Bcl-2 died as effectively as empty-vector control cells in response to ABT-737 (Figures 1a and b) , confirming that ABT-737 effectively targets Bcl-2. Bcl-B conferred resistance, as did Mcl-1 and Bfl-1, both in MOLT-4 and J16 cells. Surprisingly, despite their similar in vitro affinity for ABT-737, Bcl-xL and Bcl-w were not equivalent to Bcl-2 in their sensitivity to ABT-737. In both cell types, Bcl-xL and in particular Bcl-w conferred resistance as revealed by a right shift of the curves and increased EC 50 values (Figures 1a and b) .
Correction for protein turnover shows that Bcl-2 is the optimal target of ABT-737, preferred over Bcl-xL and Bcl-w, while Mcl-1 and Bfl-1 are untargeted. As ABT-737 seemed more selective for Bcl-2 than previously anticipated, we aimed to substantiate this finding by excluding differences in expression levels of the pro-survival Bcl-2 family members. Bfl-1 and Mcl-1 in particular are subject to constitutive ubiquitination and proteasomal turnover, 19, 20 which may affect their antiapoptotic capability. For this purpose, we stably expressed all pro-survival Bcl-2 family members in J16 cells as amino-terminal fusions with green fluorescent protein (GFP). This enabled us to flow cytometrically sort the cell lines on equal expression levels of the pro-survival Bcl-2 proteins using GFP fluorescence (Supplementary Figure 4) . We thus corrected for differences in protein turnover that played a role in the experiments depicted in Figure 1 , where untagged Bcl-2 proteins were expressed. Bcl-B expressing cells were excluded from this analysis, as they also expressed GFP as non-fusion protein, apparently due to proteolytic cleavage (Supplementary Figure 4) . The cells were exposed to a dose range of ABT-737 and cell death was assayed after 48 h, as before. Clearly, Bcl-2 was the optimal target, as Bcl-2 overexpressing cells were the only ones that displayed equal sensitivity to ABT-737 as emptyvector control cells (Figures 2a and b) . Bfl-1 and Mcl-1 were highly insensitive to ABT-737, with EC 50 values that were over 50-fold higher than those for Bcl-2. Importantly, the assay demonstrated conclusively that at equal expression levels, Bcl-xL and Bcl-w are targeted by ABT-737 with lower efficiency than Bcl-2. This is apparent from the shift in the dose-response curves (Figure 2a ) and the 10 to 20-fold higher EC 50 values (Figure 2b ). We conclude that in the cellular context, ABT-737 targets Bcl-xL and Bcl-w to a lesser extent than Bcl-2 and does not target Bfl-1 or Mcl-1.
ABT-737 and etoposide synergize more strongly in tumor cells that overexpress Bcl-2, as compared with Bcl-xL or Bcl-w. Next, we investigated in which cases ABT-737 could alleviate resistance to a conventional therapeutic regimen. To this end, we tested the cell line panel expressing the untagged pro-survival proteins for responsiveness to etoposide, a topoisomerase II inhibitor and an inducer of DNA double-strand breaks. MOLT-4 was much more sensitive to etoposide than J16 (Figure 3a ), in agreement with its wild-type p53 status. Overexpression of Bcl-2, Bcl-xL and Bcl-w strongly inhibited etoposide-induced cell death in MOLT-4 and conferred almost complete resistance against etoposide in J16, at all tested concentrations (Figure 3a) . In contrast, Bcl-B, Bfl-1 or Mcl-1 overexpression had little effect on etoposide-induced death in MOLT-4 and none in J16 (Figure 3a) . It was expected that ABT-737 would sensitize the etoposide-resistant cells for cell death induction, in case they overexpressed Bcl-2 or other ABT-737 target proteins. To test this, all cell lines were exposed to a dose range of etoposide, in the absence or presence of a low dose of ABT-737. Strikingly, the combined effect of ABT-737 and etoposide was only synergistic in case of Bcl-2 overexpression, both in MOLT-4 and J16 cells (Figure 3b ). This was defined by the calculated combination index (C.I.) of 0.54, which is below the cutoff for synergy of 0.9. In case of Bcl-B, Bfl-1 and Mcl-1, the CI was higher than 1, confirming that these proteins are not targeted by ABT-737. More importantly, in case of Bcl-xL and Bcl-w, the combined effect with ABT-737 was hardly or not at all synergistic (Figure 3b) . At a higher dose of ABT-737, synergy was observed in Bcl-xL-and Bcl-w-overexpressing cells (results not shown), confirming that these proteins were . We conclude that ABT-737 can act synergistically with a conventional DNAdamaging anticancer regimen to alleviate the apoptotic blockade imposed by Bcl-2, but to a much lesser extent that imposed by Bcl-xL or Bcl-w. This is the case in both p53 wildtype and mutant leukemic cells.
ABT-737 selectivity for Bcl-2 over Bcl-xL and Bcl-w is explained by differential displacement of BH3-only proteins and Bax. BH3-mimetics are thought to induce cell death by releasing BH3-only proteins like Bim, or an active pool of Bak/Bax from sequestration by pro-survival Bcl-2 family members. 10, 14, 17 To gain further insight into the selectivity of ABT-737 in cells, we tested its potential to displace BH3-only proteins or Bax from the different prosurvival Bcl-2 family members. We first focused on Bim that has been implicated as a major factor in sensitivity to ABT-737. 17 HEK 293T cells expressing Flag-tagged Bim, in combination with each of the HA-tagged pro-survival Bcl-2 proteins were treated for 8 h with a high dose (10 mM) of ABT-737 or solvent control. Pro-survival Bcl-2 proteins were immunoprecipitated and the amount of Bim that was bound to them was determined by western blotting (Figure 4a , left panel). Western blotting of total cell lysates indicated that overall expression levels of Bim and the inhibitory Bcl-2 proteins were comparable before and after ABT-737 treatment. Western blot signals in the immunoprecipitates were quantified and the ratio between Bim and the inhibitory Bcl-2 proteins was calculated ( Figure 4a , right panel). The amount of Bim recovered in the absence of ABT-737 was set at 100% in each case. This analysis revealed that ABT-737 could not displace Bim from Bcl-B, Bfl-1 and Mcl-1, even at this high dose, in line with the data we obtained in the cell death assays. At 10 mM, ABT-737 displaced Bim from Bcl-2 and Bcl-xL in equal measure, by about 75% (Figure 4a , right panel). Also at a lower dose range from 3 to 0.3 mM, ABT-737 displaced Bim from Bcl-2 and Bcl-xL with equal efficiency (Figure 4b) . However, at 10 mM, ABT-737 displaced Bim with significantly lower efficacy from Bcl-w than from Bcl-2 or Bcl-xL (Figure 4a, right panel) . This is in agreement with the fact that Bcl-w conferred ABT-737 resistance in our cell lines.
We considered that looking solely at disruption of Bim complexes is not fully informative of ABT-737 action, as it did not explain the differential sensitivity of Bcl-2 and Bcl-xL overexpressing cells. We therefore tested displacement of other pro-apoptotic proteins from Bcl-2 and Bcl-xL. Flagtagged Bax (Figure 4c ) or Myc-tagged Bad (Figure 4d) were expressed in conjunction with HA-tagged Bcl-2 or Bcl-xL, cells were treated for 8 h with 0.3 mM of ABT-737 or solvent control and samples were analyzed as stated before. These assays revealed that ABT-737 displaced Bax from Bcl-2 with a significantly higher efficacy than from Bcl-xL ( Figure 4c ). Moreover, Bad displacement from Bcl-2 was very efficient at this 0.3 mM dose of ABT-737, while Bad displacement from Bcl-xL was completely ineffective (Figure 4d ). Also at a high ABT-737 dose of 10 mM, Bad was still more efficiently displaced from Bcl-2 than from Bcl-xL (results not shown). These assays indicate that ABT-737 discriminates in cells between Bcl-2, Bcl-xL and Bcl-w complexes, despite similar in vitro affinity for the pro-survival proteins themselves. [21] [22] [23] To test individual BH3-only proteins for their capacity to alleviate ABT-737 resistance as mediated by all three untargeted proteins, we enabled J16 cells to inducibly express BH3-only proteins in response to doxycycline (Dox). This allowed us to specifically study the contribution of one BH3-only protein at a time, which is not possible when broadly acting stimuli are used that may activate multiple (unknown) BH3-only proteins at once. 7, 8 We tested Bim, Puma and the active carboxyterminal fragment of Bid (tBid-C), as they reportedly bind to all pro-survival Bcl-2 family members and can directly activate Bax/Bak. 3, 4, 24 We also tested Noxa, as it has a Bcl-2 family binding profile that is exactly complementary to that of ABT-737. 3, 24 The Bim-, Puma-, tBid-C-and Noxainducible cell lines that were created died in a dosedependent manner upon treatment with Dox and induction of the BH3-only proteins was confirmed by western blotting (Supplementary Figure 5) . After this validation, the cell lines were retrovirally transduced to express Bcl-B, Bfl-1 or Mcl-1, which made them resistant to ABT-737.
These cell lines were treated for 48 h with a dose range of ABT-737, in the absence or presence of Dox, after which cell death was monitored. Noxa showed a clear synergistic interaction with ABT-737 in cells that expressed either Among all pro-and antiapoptotic Bcl-2 family proteins both in J16 and MOLT-4 only Noxa was consistently upregulated at the mRNA level in both cell lines (Supplementary Figure 7) . Noxa downregulation by RNA interference was unsuccessful (results not shown), but bortezomib kills Jurkat cells via Noxa induction. 27 These results show that bortezomib upregulates Noxa expression in p53 wild-type and mutant leukemias, which is accompanied by increased sensitivity to ABT-737, despite overexpression of the non-targeted proteins Bcl-B, Bfl-1 and Mcl-1.
Discussion
Our study revealed that Bcl-2, Bcl-xL and Bcl-w are not targeted with equal efficiency by ABT-737 in the cellular context. It thereby identified Bcl-w and Bcl-xL as potential mediators of ABT-737 resistance. Although this is surprising in the light of their similar in vitro targeting, 11 other data also point in this direction. 15, [28] [29] [30] Whitecross et al. 29 reported that Bcl-w conferred resistance to ABT-737 in Em-Myc transformed mouse lymphoma cells, while Van Delft et al. 15 found that mouse embryonic fibroblasts were less sensitive to ABT-737 upon overexpression of Bcl-xL as compared with Bcl-2. Furthermore, high levels of Bcl-2, but not Bcl-xL or Bcl-w were found to correlate with ABT-737 or ABT-263 sensitivity in CLL. 17, 30 Also, Tahir et al. 31 found a positive correlation between ABT-263 resistance and high Bcl-w mRNA levels in SCLC cell lines and with high Bcl-xL and low Bcl-2 protein levels in leukemia cell lines. Nevertheless, a major dose-limiting toxicity of ABT-263 in patients is apoptosis of platelets that depend on Bcl-xL for their survival. 32, 33 It appears therefore that Bcl-xL can mediate resistance in some cell types, but that it is efficiently targeted in others. Our findings offer an explanation for this paradox. ABT-737 induces apoptosis by disrupting pre-existing complexes between pro-and antiapoptotic Bcl-2 family proteins. We demonstrate that its ability to do so is different for different complexes, which explains the differential targeting of Bcl-xL and Bcl-w observed in cells. ABT-737 displaced Bim with lower efficiency from Bcl-w than from Bcl-xL or Bcl-2 ( Figure 4) . ABT-737 displaced Bim with similar efficiency from Bcl-2 and Bcl-xL, but differential targeting of Bcl-2 and Bcl-xL became apparent when we examined displacement of Bax and Bad. Our data indicate that not the binding affinity for the pro-survival Bcl-2 proteins as such, but rather the ability to disrupt complexes with their pro-apoptotic relatives determines the potency of ABT-737 and ABT-263. The fact that complexes of pro-survival Bcl-2 proteins are targeted, rather than the 'empty' molecules, is important for the therapeutic window of BH3-mimetics. ABT-263 has dose-limiting normal tissue toxicity in patients, due to thrombocytopenia and T-cell lymphopenia. 33 Platelets rely on Bcl-xL for survival, which seems to be dependent on sequestration of Bak 32 and not Bid or Bim. 34 Compounds that would specifically disrupt Bcl-xL complexed with Bim but not with Bak may therefore be more tumor-selective and less toxic on normal tissue.
In our comprehensive specificity profiling, we consistently found that Bfl-1-and Mcl-1-mediated ABT-737 resistance, confirming data by others. [14] [15] [16] 28, 29 We found likewise that Bcl-B caused ABT-737 resistance in both cell lines. This is a novel finding, consistent with the low in vitro affinity of ABT-737 for Bcl-B.
11 Bcl-B was recently found to be upregulated in primary CLL upon ABT-737 treatment and suggested to contribute to ABT-737 resistance. 30 Bcl-B is also expressed in diffuse large B-cell lymphoma and SCLC, which are tumor types currently treated with ABT-263 in clinical trials 13, 33 and it may therefore be of value as a predictive marker.
ABT-737 is presently under clinical evaluation as a singleagent therapy, but preclinical studies emphasize its improved potential in combined modality therapies. 9 Many studies have focused on Mcl-1 neutralization to achieve synergy between ABT-737 and other drugs, 9,35 but we aimed to identify the BH3-only protein(s) that overrule ABT-737 resistance, as conferred by all untargeted pro-survival Bcl-2 proteins. We tested Puma, Bim and tBid-C, as they reportedly interact with all pro-survival Bcl-2 proteins and Noxa because it is known to neutralize Mcl-1. 24 Although Puma and Bim have been previously suggested to synergize with ABT-737, 21, 22 our data show that only Noxa provided synergy, in case of Mcl-1, Bfl-1, as well as Bcl-B overexpression. This is most likely because of its complementarity, as Noxa cannot only interact with Mcl-1, but also with Bfl-1 20 and with Bcl-B, as we have recently found (data not shown). These findings are corroborated by a vast amount of literature that implies Noxa as a crucial determinant of ABT-737 sensitivity in various tumor cell lines and in synergy with diverse agents. 9, 23, 31 However, we are the first to show that selective induction of Noxa, but not Bim, Puma or tBid-C, alleviates ABT-737 resistance not only as imposed by Mcl-1, but by all three untargeted prosurvival proteins. In accordance, loss of Noxa, and not any other BH3-only protein, was found in a genome-wide screen in chronic myeloid leukemia cells as a key determinant for ABT-737 resistance. 36 Thus, Noxa induction is the optimal remedy to overcome ABT-737 resistance as conveyed by Mcl-1, Bfl-1, as well as Bcl-B.
Given the occurrence of tumor cell resistance and normal tissue toxicity, the search is on for new BH3-mimetics that more selectively target certain pro-survival Bcl-2 family proteins, including those that are untargeted by ABT-263. Our work implies that such drugs must be selected for the ability to compete with BH3 domains from different pro-apoptotic Lysates were prepared and analyzed by western blotting for Noxa protein induction, using a Noxa-specific antibody. The blot was re-probed with an Actinspecific antibody to confirm equal loading proteins in binding to pro-survival Bcl-2 family members. This will be necessary to find the compounds that most effectively kill tumor cells, but also provide a therapeutic window in regards to normal tissue toxicity.
Materials and Methods
Constructs. Vectors encoding Bcl-2, Bfl-1, or tBid-C have been described previously. 37 Vectors encoding Bcl-xL, Mcl-1, Noxa, Puma or Bax were kindly provided by various investigators. cDNA clones for Bcl-w, Bcl-B, Bad, Bim were obtained from the IMAGE library (ImaGenes, Berlin, Germany). For stable expression in MOLT-4 or J16 cells, cDNAs encoding all six pro-survival Bcl-2 proteins were cloned into the retroviral vector pMX-IRES-Blasticidin for expression as untagged protein, or into LZRS-GFP-IRES-Zeo for expression as N-terminally GFP-tagged fusion protein. For Dox-inducible, stable expression in J16 cells, HAtagged Bid, Bim, Noxa and Puma cDNA 0 s were cloned into the lentiviral vector pLVX-Tight (Clontech, Mountain View, CA, USA). For transfection into HEK 293T cells, they were cloned in frame into the pHA-C2 vector, a modified version of pEGFP-C2 (Clontech), in which EGFP has been replaced by a double HA-tag (kindly provided by L Janssen, The Netherlands Cancer Institute, Amsterdam, The Netherlands). The cDNA encoding Bim or Bax was cloned into the vector p3xFlag (Sigma-Aldrich, St. Louis, MO, USA) and cDNA of Bad was cloned into pCDNA3 (Invitrogen, Carlsbad, CA, USA) that encodes a double Myc-tag. All cDNA clones used encode the full-length human proteins. All cloning was done using standard cloning and PCR techniques. All constructs were verified by dideoxynucleotide sequencing.
Cell lines. Two T-ALL cell lines were used as model systems in this study: The p53-mutant Jurkat derived clone J16 37 and the p53 wild-type cell line MOLT-4.
38
The p53 status of the cell lines was confirmed by sequencing of all exons of the p53 gene (data not shown). J16 and MOLT-4 cell lines stably overexpressing unmodified pro-survival Bcl-2 family members were obtained by retroviral transduction with pMX-IRES-Blasticidin. Cell lines expressing the pro-survival Bcl-2 proteins as amino-terminally GFP-tagged fusions were obtained using the LZRS-GFP-IRES-Zeo vector. To get equal GFP-fusion Bcl-2 protein expression after transductions, the resulting cell lines were selected on Zeocin for 2 weeks, and subsequently sorted on equal GFP signal using a FACSAria (BD Biosciences, San Jose, CA, USA). J16 cell lines with stable, Dox-inducible expression of BH3-only proteins were created by sequential lentiviral transduction with pLVX-Tet-On Advanced (Clontech) and pLVX-tight encoding the BH3-only proteins. Confirmed clones were retrovirally transduced to stably express the untagged versions of Bcl-B, Bfl-1 or Mcl-1, to make them resistant to ABT-737. Methodology used for virus production, gene transduction and cell selection is detailed in the Supplementary Information. Cell lines were cultured in either IMDM (J16 and MOLT-4) or DMEM (Phoenix-Ampho and HEK 293T), supplemented with 8% heat-inactivated fetal bovine serum and antibiotics in a humidified incubator at 37 1C and 5% CO 2 .
